Results: A total of 150
chemotherapy cycles were administrated for 88 patients (75 in the
olanzapine 5 mg group and 75 in the
olanzapine 10 mg group). The proportions of CR in the
olanzapine 5 mg group were comparable to those in the
olanzapine 10 mg group in acute (93.3% vs. 94.7%, P = 0.731), delayed (76% vs. 78.7%, P = 0.697), and overall phase (73.3% vs. 77.3%, P = 0.570). Moreover, no
nausea rates were also comparable between the two groups in acute (76% vs. 78.7%, P = 0.697), delayed (54.7% vs. 60%, P = 0.509), and overall period (50.7% vs. 57.3%, P = 0.111). Regarding the adverse effects, the incidence of
somnolence in the 10 mg group (58.6%) was significantly higher than that in the 5 mg group (41.3%) (P = 0.034), while
constipation (20.0% vs. 24.0%, P = 0.554) and
hiccups (9.3% vs. 10.6%, P = 0.785) rates were comparable in two groups.
Conclusions: